Legal & General Group’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-3,029
| Closed | -$4.82K | – | 3578 |
|
|
2024
Q1 | $4.82K | Hold |
3,029
| – | – | ﹤0.01% | 3301 |
|
|
2023
Q4 | $2.6K | Hold |
3,029
| – | – | ﹤0.01% | 3358 |
|
|
2023
Q3 | $3.24K | Sell |
3,029
-24,882
| -89% | -$51.5K | ﹤0.01% | 3387 |
|
|
2023
Q2 | $72.2K | Buy |
27,911
+15,509
| +125% | +$55.3K | ﹤0.01% | 2843 |
|
|
2023
Q1 | $50.6K | Buy |
12,402
+796
| +7% | +$3.68K | ﹤0.01% | 2874 |
|
|
2022
Q4 | $58.3K | Hold |
11,606
| – | – | ﹤0.01% | 2923 |
|
|
2022
Q3 | $151K | Buy |
11,606
+940
| +9% | +$14.2K | ﹤0.01% | 2710 |
|
|
2022
Q2 | $137K | Buy |
10,666
+148
| +1% | +$2.05K | ﹤0.01% | 2768 |
|
|
2022
Q1 | $160K | Hold |
10,518
| – | – | ﹤0.01% | 2744 |
|
|
2021
Q4 | $186K | Hold |
10,518
| – | – | ﹤0.01% | 2751 |
|
|
2021
Q3 | $221K | Buy |
10,518
+6,063
| +136% | +$133K | ﹤0.01% | 2653 |
|
|
2021
Q2 | $87K | Buy |
4,455
+1,713
| +62% | +$40.1K | ﹤0.01% | 2787 |
|
|
2021
Q1 | $80K | Sell |
2,742
-108
| -4% | -$3.02K | ﹤0.01% | 2678 |
|
|
2020
Q4 | $86K | Hold |
2,850
| – | – | ﹤0.01% | 2627 |
|
|
2020
Q3 | $45K | Sell |
2,850
-944
| -25% | -$17.2K | ﹤0.01% | 2733 |
|
|
2020
Q2 | $75K | Buy |
3,794
+45
| +1% | +$860 | ﹤0.01% | 2609 |
|
|
2020
Q1 | $49K | Sell |
3,749
-1,257
| -25% | -$20.5K | ﹤0.01% | 2596 |
|
|
2019
Q4 | $92K | Buy |
5,006
+4,006
| +401% | +$58.6K | ﹤0.01% | 2616 |
|
|
2019
Q3 | $14K | Hold |
1,000
| – | – | ﹤0.01% | 3216 |
|
|
2019
Q2 | $15K | Buy |
+1,000
| New | +$14.6K | ﹤0.01% | 3282 |
|
Legal & General Group's NGM Position: Q2 2024 in Review
Legal & General Group sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 3,029 shares — an estimated $4.82K sold.
Legal & General Group first reported a position in NGM in Q2 2019 and held it in 20 quarters. The position peaked at $221K in Q3 2021. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Legal & General Group reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Legal & General Group sold 3,029 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $4.82K.
- Legal & General Group first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 20 quarters.
- Legal & General Group's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $221K in Q3 2021.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Legal & General Group's 13F filing for Q2 2024, filed 14 Aug 2024.